Artera

Artera is a precision oncology company that develops multimodal artificial intelligence (MMAI) tests combining digitized pathology images with structured clinical data to produce prognostic and predictive outputs for cancer treatment planning. Its lead product, the ArteraAI Prostate Test, is offered in biopsy and post-radical-prostatectomy versions and is intended for adult males 18 or older with localized prostate cancer without clinically or pathologically defined metastases who are candidates for curative-intent management (surgery, radiation therapy with or without systemic therapy, or active surveillance). The test estimates long-term outcomes including distant metastasis, biochemical failure, prostate cancer-specific survival and overall survival, and predicts whether a patient is likely to benefit from short-term androgen deprivation therapy (ST-ADT) alongside radiation. The company also markets an ArteraAI Breast Cancer Test that reports 5- and 10-year distant metastasis risk for early-stage breast cancer and predicts chemotherapy benefit in node-negative patients aged 50 and older.

The prostate test is described as a laboratory-developed test performed at the company's CLIA-certified high-complexity laboratory at 6800 Southpoint Pkwy Suite 950, Jacksonville, Florida. Analysis uses image data from existing H&E slides, requiring no additional staining, procedures or tissue consumption, with results typically available within one to two days of specimen receipt and delivered through an online clinician portal or by fax. Separately, the company states that ArteraAI Prostate received FDA Breakthrough Device Designation and subsequently De Novo marketing authorization as a risk-stratification tool for nonmetastatic prostate cancer regulated as Software as a Medical Device; the company is identified in that context as based in Los Altos, California. In June 2026 Artera announced an expansion of the platform to metastatic hormone-sensitive prostate cancer (mHSPC), described as the first digital pathology-based test providing individual risk estimates to inform mHSPC treatment planning.

Note on name twins: a separate company operating at artera.io — a Santa Barbara-based healthcare patient-communications and agentic AI vendor founded in 2015 by CEO Guillaume de Zwirek — shares the Artera name but is a different business; its funding and metrics are excluded from this profile.

Business model

Artera commercializes AI-based diagnostic tests. The ArteraAI Prostate Test is run as a laboratory-developed test in the company's own CLIA-certified laboratory; clinicians order through an Artera Portal account, and the company's customer success team coordinates shipment of histopathology samples from the pathology lab to the Florida laboratory. Outside the United States, versions of the test are made available through partners.

Test-based revenue reimbursed through payers: Medicare (CMS) has established a payment rate for the ArteraAI Prostate Test, which the company says is fully reimbursed for Medicare patients, and many commercial health plans provide coverage. A financial assistance program is offered to commercially insured patients facing large out-of-pocket costs.

Traction

The prostate test can be ordered in all 50 US states, with partner-enabled availability in Puerto Rico, the United Kingdom, Australia and Israel. Reported clinical validation figures include a cohort in which 34% of patients were identified as likely to benefit substantially from short-term hormone therapy: AI biomarker-positive patients (n=673) showed a hazard ratio of 0.34 (95% CI 0.19-0.63, P<0.001) versus 0.92 (95% CI 0.59-1.43, P=0.71) for biomarker-negative patients (n=1,046), interaction p-value 0.002.

Latest developments

On 2026-06-04 Artera announced expansion of its validated multimodal AI platform to metastatic hormone-sensitive prostate cancer, described as the first digital pathology-based test to provide individual risk estimates for mHSPC treatment planning; the test is listed as now available on the company homepage. The FDA granted De Novo marketing authorization to ArteraAI Prostate for nonmetastatic prostate cancer risk stratification. The company is also listed as exhibiting at the ASTRO 68th Annual Meeting in Boston, September 26-30, 2026.